Innate Pharma (IPHA) Other Gross PP&E Adjustments (2020 - 2025)
Historic Other Gross PP&E Adjustments for Innate Pharma (IPHA) over the last 6 years, with Q2 2025 value amounting to $5.8 million.
- Innate Pharma's Other Gross PP&E Adjustments fell 1465.52% to $5.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was $5.8 million, marking a year-over-year decrease of 1465.52%. This contributed to the annual value of $6.8 million for FY2024, which is N/A changed from last year.
- Innate Pharma's Other Gross PP&E Adjustments amounted to $5.8 million in Q2 2025, which was down 1465.52% from $6.8 million recorded in Q4 2024.
- Innate Pharma's 5-year Other Gross PP&E Adjustments high stood at $14.1 million for Q2 2021, and its period low was $5.8 million during Q2 2025.
- For the 5-year period, Innate Pharma's Other Gross PP&E Adjustments averaged around $8.9 million, with its median value being $8.1 million (2023).
- As far as peak fluctuations go, Innate Pharma's Other Gross PP&E Adjustments soared by 954.02% in 2021, and later tumbled by 2680.73% in 2024.
- Over the past 5 years, Innate Pharma's Other Gross PP&E Adjustments (Quarter) stood at $14.1 million in 2021, then fell by 22.91% to $10.9 million in 2022, then dropped by 14.32% to $9.3 million in 2023, then fell by 27.37% to $6.8 million in 2024, then fell by 13.99% to $5.8 million in 2025.
- Its Other Gross PP&E Adjustments stands at $5.8 million for Q2 2025, versus $6.8 million for Q4 2024 and $6.8 million for Q2 2024.